Volcano Corporation (NYSE:VOLC) recently made an announcement related to their new two year results of their largest prospective study of the use of IVUS in Stent placement. From the analysis, the use of intravascular ultrasound which is also known as IVUS in the ADAPT – DES that is also known as Assessment of dual Anti Platelet therapy with drug eluted stents was told. This is the largest prospective registry of IVUS.
The results of the test suggest that in the ADAPT – DES study, the use of IVUS with angiography in order to place the current generation of drug eluting stents being used now would help in reduction of some of the risks in events of certain serious patients. This also includes stent thrombosis with myocardial infarctions as well as the target lesion revascularizations. This is being considered for the patients who are suffering from severe complex lesions.
This two year data was presented and suggested by Bernhard Witzenbichler who is the Managing Director and the study investigator of Volcano Corporation during an oral presentation session at the event of 25th Annual Transcatheter Cardiovascular Therapeutics scientific symposium. This event is sponsored by The Cardiovascular Research Foundation.
The one year study data was presented in the year 2012 at the Transcatheter Cardiovascular Therapeutics and the 2 year study is an extension of the one year data made available in the year 2012.
The two year study is especially encouraging the suggested positive association between IVUS use and the patients outcomes reported by the ADAPT – DES study. It would help in increasing the benefits in the patients there by improving their condition.
Volcano Corporation is a leading manufacturer and developer of precision guided tools and techniques which helps in enhancement of treatment and diagnosis of peripheral and coronary diseases.